Please assess the completion status of the following clinical trial:

Trial Title: Hydrogel Endovascular Aneurysm Treatment Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Candidates for this study must meet the following criteria to be enrolled in the study:~1. Patient is between 18 and 75 years of age (inclusive).~2. Patient has a documented untreated intracranial saccular aneurysm 3-14 mm diameter angiographic lumen, ruptured or unruptured, suitable for embolization with coils.~3. Patients presenting with a HUNT and HESS Grade 0-3 or improving to such a grade before treatment~4. Any type of bare platinum coils and HydroCoil ® Coils are treatment options (all shapes allowed).~5. Patient or next of kin or person with appropriate power of attorney has provided written informed consent.~6. Patient is willing and available for study follow-up visits~7. Patient has not been previously entered into this Study~Exclusion Criteria:~Candidates will be ineligible for enrollment in the study if any of the following conditions apply:~1. Inability to obtain informed consent~2. Patient is \< 18 or \> 75 years old~3. Target aneurysm is not saccular in nature (mycotic, fusiform, dissecting).~4. Target aneurysm is \> 14 mm maximum luminal dimension, \< 3 mm maximum luminal dimension~5. Target aneurysm has been previously clipped or coiled~6. Target aneurysm is in the physician's estimate unlikely to be successfully treated by endovascular techniques.~7. Patient has known hypersensitivity to platinum, nickel, stainless steel or structurally related compounds found in HydroCoil®, HydroSoft®, HydroFrame® Coils and/or bare platinum coils.~8. Baseline Hunt and Hess scale 4 or 5 for ruptured aneurysms~9. Intended use of a flow diverting stent (e.g. pipeline)~10. Subject has concurrent intracranial pathology, e.g.~    * Moyamoya~   * Vasculitis documented by biopsy results~   * AVMs~   * AV fistulas~   * Significant atherosclerotic disease (i.e. symptomatic and or \>50% narrowing of the parent arteries necessary to traverse in order to coil the target aneurysm)~   * Intracranial Hematoma (unrelated to the target aneurysm)~   * Brain tumors~   * Vascular tortuosity and other conditions preventing access to target aneurysm~11. Subject has serious co-morbidities that could confound the study results:~    * Uncontrolled hypertension~   * Uncorrectable coagulation abnormality~   * Contraindications for heparin, aspirin or clopidogrel~   * Uncontrolled Diabetes Mellitus~   * Organ failure of kidney, liver, heart, or lung~   * Myocardial infarction within the past 6 months~   * Cancer likely to cause death within 2 years or less.~12. Subject history indicates high risk of non-compliance (e.g., substance abuse, psychosocial issues, etc.)~13. Subject has a known history contraindicating contrast dye or iodine that cannot be pre-medicated prior to coiling procedure (vs. sensitivity which can be safely controlled by antihistamine, steroid, etc.). Medical clearance will be needed for this issue.~14. Patients who are unable to complete scheduled follow up assessments at the enrolling center due to limited life expectancy (\<2 years), co-morbidities or geographical considerations~15. Subject is currently breast feeding, pregnant or plans to become pregnant in the next 2 years.~16. Major surgical procedure or trauma within 30 days prior to randomization~17. The patient is currently enrolled in another clinical study (device or drug).~18. More than one aneurysm needing treatment at the same time.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- HydroCoil Embolic System (Type: OTHER): Aneurysm treatment using the HydroCoil Embolization System (21 CFR 882.5950)
- Control (Type: OTHER): Aneurysm treatment using bare platinum coil(s)

Based on this trial design, predict the completion outcome and termination type (if applicable).